Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.84 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.84 |
| ▸ | AKT1 | P31749 | 2/20 | 0.78 |
| ▸ | PDE5A | O76074 | 2/20 | 0.73 |
| ▸ | ESR1 | P03372 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.73 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.63 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.63 |
| ▸ | PTGES | O14684 | 1/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20045165 | 0.92 | DYRK1A (1.00) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL20045166 | 0.91 | DYRK1A (0.71) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL28950297 | 0.89 | SLC22A2 (0.72) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL3192297 | 0.89 | AKT1 (0.71) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL4828372 | 0.88 | AKT1 (1.00) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL4227433 | 0.87 | PDE5A (0.80) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL27013412 | 0.86 | AKT1 (0.83) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL29808704 | 0.86 | AKT1 (0.83) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL1231403 | 0.85 | PDE4D (1.00) | DYRK1ADYRK1BAKT1PDE5AESR1 | |
| SCHEMBL29808504 | 0.85 | PDE4D (1.00) | DYRK1ADYRK1BAKT1PDE5AESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144901-A1 | CUSTOMIZABLE LYOPHILIZED AGENT FOR IMAGE-GUIDED RADIOTHERAPY AND DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-05-28 | — | — | US | claimed |
| US-20250381166-A1 | Cannabis-Derived Flavonoids And Related Methods | CANURTA INC (CA) | 2025-12-18 | — | — | US | claimed |
| WO-2025137725-A2 | A METHOD OF CULTIVATING, PREPARING, AND USING A MATRIX-BLANK BIOMASS | PAULI CHRISTOPHER STEPHEN (US) | 2025-06-26 | — | — | WO | claimed |
| US-20240315965-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2024-09-26 | — | — | US | claimed |
| US-20240050512-A1 | REDUCTION OF VIRAL INFECTIONS | PHOXBIO LIMITED (IE) | 2024-02-15 | — | — | US | claimed |
| US-20240026314-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | ROTHSTEIN STEVEN (CA) | 2024-01-25 | — | — | US | claimed |
| US-20240018114-A1 | PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS | DEYI PHARMACEUTICAL LTD. (CN) | 2024-01-18 | — | — | US | claimed |
| EP-4250991-A1 | REDUCTION OF VIRAL INFECTIONS | Phoxbio Limited (IE) | 2023-10-04 | — | — | EP | claimed |
| EP-4251758-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | Rothstein, Steven (CA) | 2023-10-04 | — | — | EP | claimed |
| EP-4223748-A1 | PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS | Deyi Pharmaceutical Ltd. (CN) | 2023-08-09 | — | — | EP | claimed |
| WO-2023141695-A1 | CANNABIS-DERIVED FLAVONOIDS AND RELATED METHODS | CANURTA INC. (CA) | 2023-08-03 | — | — | WO | claimed |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2023-03-23 | — | — | US | claimed |
| WO-2022182523-A1 | COMPOSITIONS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022182527-A1 | COMPOSITIONS AND METHODS RELATED TO PHARMACEUTICAL EXCIPIENTS | Natural Extraction Systems, LLC (US) | 2022-09-01 | — | — | WO | claimed |
| WO-2022109736-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | ROTHSTEIN STEVEN (CA) | 2022-06-02 | — | — | WO | claimed |
| WO-2022112430-A1 | REDUCTION OF VIRAL INFECTIONS | PHOXBIO LIMITED (IE) | 2022-06-02 | — | — | WO | claimed |
| US-20260144901-A1 | CUSTOMIZABLE LYOPHILIZED AGENT FOR IMAGE-GUIDED RADIOTHERAPY AND DRUG DELIVERY | THE JOHNS HOPKINS UNIVERSITY (US) | 2026-05-28 | — | — | US | disclosed |
| US-20250381204-A1 | A CANNABINOID MIXTURE WITH TERPENES FOR THE TREATMENT OF ANXIETY | TTS PHARMA LTD (GB) | 2025-12-18 | — | — | US | disclosed |
| US-20180098961-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS | FLAVOCURE BIOTECH, INC. | 2018-04-12 | — | — | US | disclosed |
| US-20180098961-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS | FLAVOCURE BIOTECH, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381204-A1 | A CANNABINOID MIXTURE WITH TERPENES FOR THE TREATMENT OF ANXIETY | CNR1, CNR2, CTNND1 | DYRK1A 1356/4885DYRK1B 1466/4885AKT1 1768/4885 |
| US-20230089351-A1 | METHODS RELATED TO BIOACTIVE AGENTS THAT CONVERT FROM ANIONS TO MOLECULES | FABP2, FABP4, GUSB | DYRK1A 4736/4885DYRK1B 4723/4885AKT1 357/4885 |
| US-20240018114-A1 | PREPARATION METHOD FOR CANNFLAVIN COMPOUNDS | HSPB1, HMBS, CYP8B1 | DYRK1A 3443/4885DYRK1B 2112/4885AKT1 2743/4885 |
| US-20240050512-A1 | REDUCTION OF VIRAL INFECTIONS | TFRC, ZFR, HAMP | DYRK1A 4879/4885DYRK1B 4877/4885AKT1 3695/4885 |
| US-20180098961-A1 | THERAPEUTIC AGENTS CONTAINING CANNABIS FLAVONOID DERIVATIVES TARGETING KINASES, SIRTUINS AND ONCOGENIC AGENTS FOR THE TREATMENT OF CANCERS | BRDT, BRD4, CKS2 | DYRK1A 2472/4885DYRK1B 2251/4885AKT1 450/4885 |
| US-20260144901-A1 | CUSTOMIZABLE LYOPHILIZED AGENT FOR IMAGE-GUIDED RADIOTHERAPY AND DRUG DELIVERY | GZMB, CTSZ, SLC39A11 | DYRK1A 986/4885DYRK1B 538/4885AKT1 2635/4885 |
| US-20240026314-A1 | POLYPEPTIDES FOR USE IN THE SYNTHESIS OF BIOACTIVE PHENOLIC COMPOUNDS | COMT, PNMT, GNMT | DYRK1A 4386/4885DYRK1B 4349/4885AKT1 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.